# Eculizumab Biosimilar, N297A Mutant | Catalog C022P.NA

Eculizumab Biosimilar, N297A Mutant. Eculizumab biosimilar CHO stable cell line is available for licensing to manufacture the eculizumab biosimilar protein. The research grade eculizumab biosimilar protein is for research use only (RUO). Recombinant human IgG4 isotype controls and recombinant human IgG2 isotype controls are available.

## Product Specifications

| | |
|---|---|
| **Catalog No.** | C022P.NA |
| **Product Name** | Eculizumab Biosimilar, N297A Mutant |
| **Supplier Name** | Syd Labs, Inc. |
| **Brand Name** | Syd Labs |
| **Synonyms** | Research Grade Anti-Complement Protein C5 Humanized Monoclonal Antibody |
| **Summary** | Recombinant Humanized IgG2 Monoclonal Antibody. |
| **Isotype** | Human IgG2/4 N297A Mutant |
| **Source/Host** | Produced in the eculizumab biosimilar CHO stable cell line. |
| **Specificity** | Specifically binds to human C5, the terminal complement component 5. |

## Properties & Storage

| | |
|---|---|
| **Applications** | ELISA, functional assays such as bioanalytical PK and ADA assays. |
| **Formulation** | 0.2 µM filtered solution, pH 6.0, no stabilizers or preservatives. |
| **Endotoxin** | < 1 EU per 1 mg of the protein by the LAL method. |
| **Purity** | >95% by SDS-PAGE under reducing conditions and HPLC. |
| **Shipping** | Shipped with ice pack. Store immediately at recommended temperature. |
| **Storage** | 12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles. |

## Background & Description

Eculizumab, a recombinant humanized anti-C5 (terminal complement component 5) monoclonal antibody, selectively targets and inhibits the terminal portion of the complement cascade. Eculizumab is a first-in-class terminal complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

When activated, C5 at a late stage in the complement cascade is involved in activating host cells, attracting pro-inflammatory immune cells, and destroying cells by triggering pore formation. Eculizumab specifically binds to C5 and inhibits the cleavage of C5 to C5a and C5b, preventing the generation of the terminal complement complex C5b-9.